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ABSTRACT:  
There is a crucial need to identify and test sustainable alternatives to fish oil as a means to 
supplement dietary omega (n-3) fatty acids which have demonstrated health benefits to humans 
with metabolic syndrome and its associated diseases.  Echium oil has a high content of the n-3 
fatty acid stearidonic acid (SDA), a precursor of the bioactive lipids eicosapentaenoic acid (EPA) 
and docosahexaenoic acid (DHA) found in fatty cold-water fish, with known or possible 
functions to improve metabolism and delay the onset of or prevent diabetes. To characterize the 
effects of dietary Echium oil (EO) vs. fish oil (FO), the oils were formulated into either a low-fat 
(10% kcal; LF) or high-fat (60% kcal; HF) diabetogenic diet and fed to male C57BL/6Tac mice 
for 12 weeks. Compared to the low-fat or high-fat controls without the supplementation of EO or 
FO, EO and FO diets had no effect on blood glucose concentrations or plasma insulin levels 
throughout the study. The EO-enriched HF diet improved glucose tolerance by week 12 
compared to the HF-CON (p<0.05) and HF-FO (p<0.1) groups.  EO supplementation reduced 
visceral fat weight without affecting body mass, promoted a metabolically favorable high 
polyunsaturated fatty acid (PUFA) to saturated fatty acid (SFA) ratio in adipose and muscle 
tissues compared to the HF-CON and HF-FO diet groups, and led to higher tissue EPA and DHA 
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concentrations compared to both LF and HF CON (p<0.1). Tissue EPA and DHA in EO were 
not as high as the concentrations found in mice fed the FO diets for both HF and LF.  In 
conclusion, EO-supplemented diets in mice appear to have distinct effects from FO diets that 
may be exploited in future strategies to curtail metabolic disorders.
 
INTRODUCTION:  
Type 2 Diabetes (T2D) is a major worldwide epidemic with a current prevalence of ~300 million 
people with an expected 50% increase by 2025 [7]. The major risk factors for diabetes are 
obesity and the so-called “metabolic syndrome”, whereby one-third of the U.S. population is 
afflicted [5]. The costs for diabetes and its complications in the U.S. alone are upwards of $200 
billion annually [5]. Lifestyle intervention plays a major role in T2D susceptibility. There is 
growing evidence that diets rich in specific bioactive lipids such as “omega-3” (n-3) 
polyunsaturated fatty acids (PUFAs) found in fatty cold-water fish have protective roles in the 
development of the metabolic syndrome and T2D [10,16]. 
The n-3 PUFAs have received considerable research focus over the last several years, especially 
with respect to decreased risk for cardiovascular disease, inflammatory disorders, and the 
metabolic syndrome, although recent meta-analyses from human clinical trials (reviewed in [18]) 
note some inconsistencies in regards to PUFA-associated protection from T2D among different 
populations. These beneficial fatty acids, enriched in fatty fish, consist principally of 
docosahexaenoic acid (DHA) and eicosapentaenoic acid (EPA) and serve as potent ligands 
activating the G-protein coupled receptor (GPCR, “GPR120”), a key receptor on cell membranes 
that aids in anti-inflammatory signaling, on adipocytes, and macrophages [16]. These molecules 
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effectively promote anti-inflammatory signaling cascades that lead to improved insulin 
sensitivity [11]. Insulin is exclusively made and secreted from a pancreatic endocrine cell type 
called β-cells, which are found in aggregates called “islets” in the pancreas.  β-cell failure or loss 
is the underlying cause of all forms of diabetes [14]. Both diet-derived and genetically 
augmented tissue production of n-3 PUFAs exhibit a strong protective effect on pancreatic ß-
cells as demonstrated by mouse transgenic Δ3-desaturase overexpression studies [1]. These 
lipids show promise to ameliorate or prevent both T1D [1] and T2D [17] due to their 
effectiveness in reducing inflammation and promoting insulin secretion [9]. Importantly, it 
appears that the proportion of the “omega-6” (n-6) PUFAs to n-3 PUFAs is key to maintaining ß-
cell protection from inflammatory mediators [19]. However, this may be a challenging feat with 
current fish oil dietary interventions, due to several aversive effects found upon fish oil 
supplementation such as stomach discomfort, bad taste, and the fact that it is not vegetarian-
friendly [18]. 
Recently, there has been significant interest in identifying sustainable plant sources rich in n-3 
PUFAs, or their precursors, as an alternative to fish and fish oil supplements [17]. One of the 
more promising plants identified is Echium plantagineum with stearidonic acid (SDA, C18:4 n-
3) instead of ALA (18:3 n-3) as a large constituent of the n-3 PUFAs in the seed oil. SDA is 
central in the biosynthetic pathway leading to the potent n-3 PUFAs in fish oil, DHA and EPA. 
In mammals, however, it appears that only EPA is metabolized in physiologically significant 
amounts from SDA [17]. Clinical studies suggest that an SDA consumption of > 9g/d (~130 
mg/kg/d) may be necessary to observe positive health effects due to its conversion efficiency 
[17]. Although there is no pre-clinical data to date on the efficacy of dietary SDA on metabolic 
outcomes, SDA supplementation is a promising strategy to test the effects of plant derived n-3 
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lipid precursors to improve metabolism, and decrease the severity, or perhaps prevent diabetes 
development. 
The goal of this study was to determine if the dietary Echium oil-derived n-3 PUFA SDA is 
comparable to fish oil-derived EPA and DHA with respect to improving metabolic outcomes in a 
high saturated fat diet-induced obesity mouse model.  Since Echium oil supplementation, as 
opposed to fish oil, has been reported to significantly lower certain plasma lipids associated with 
the metabolic syndrome in humans [2, 8, 10, 17] as an initial step in characterizing potential 
differences in how fish vs. plant sources of dietary n-3 PUFAs impact whole body energy 
physiology, we compared glucose homeostasis and tissue-specific fatty acid partitioning between 
Echium and fish oil as a function of a low- vs. high-fat diet. 
 
MATERIALS AND METHODS:  
Animals and feeding regimen. Six week-old male C57BL/6NTac mice (B6; Taconic), previously 
weaned onto a control chow (LabDiet 5001; 13.5% fat) and housed in the UVM Animal Facility, 
were ad libitum fed either a low-fat (Research Diets D12450B; 10% kcal from fat) or a high-fat 
diet (Research Diets D14292; 60% kcal from fat) supplemented with n-3 PUFAs for 12 weeks 
(Table 1).  Echium oil (EO; 20% of total fat content), menhaden fish oil (FO; 20% of total fat 
content; positive control n-3 PUFA source), or no supplement (CON; negative control; 
diabetogenic diet) were formulated separately into either the high-fat or low-fat diet (Table 2). 
The mice were grouped randomly in cages of five individuals and subjected to one of the six 
diets (n=10).  The guidelines specified by the UVM Institutional Animal Use and Care 
Committee were strictly followed for these studies.   
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Metabolic and glucose homeostasis assessments.   Body weight, fed blood glucose concentration 
(FreeStyle monitor; Abbott) and plasma insulin (ELISA; Alpco) values were measured weekly.  
Intraperitoneal glucose tolerance tests (IPGTT), an index of glucose clearance as a function of 
both glucose uptake (primarily by skeletal muscle) and pancreatic ß-cell function, was carried 
out at 4, 8, and 12 week time-points. Following a 12 h fast, mice (n=5) were given an IP bolus of 
glucose (2g/kg) and blood glucose was measured at 0, 15, 30, 60, 90, and 120 minutes. For 
intraperitoneal insulin tolerance tests (IPITT), an index of insulin sensitivity, a different group of 
mice (n=5) was tested at 8 and 12 weeks. Following a 12 h fast, mice were given insulin at 
0.75U/kg by an IP injection, and blood glucose was measured at 0, 15, 30, 60, 90, and 120 
minutes.  
Tissue collection.  At 12 weeks, mice were euthanized with a lethal dose of pentobarbital 
(Sleepaway), and pancreas, liver, epididymal fat, quadriceps muscle, spleen, and blood were 
rapidly collected. The liver, pancreas, and fat pad were weighed for comparisons between 
groups.  Tissues were snap frozen in liquid nitrogen and subsequently stored at -80˚C prior to 
analyses, whereas heparinized blood was immediately separated into cells and plasma fractions 
before storing at -20˚C. 
Fatty acid analysis of feed.  Food consumption was determined biweekly and samples from the 
refusals and fresh food were removed and stored at -20° C to determine the fatty acid profile and 
any potential degradation (i.e., oxidation) of the fatty acids of the feed. There was no difference 
between the refusals and the fresh food. Fatty acid content and profile of the feed samples were 
analyzed using a modified version of the direct transesterification method developed by Sukhija 
and Palmquist (1988) [15].  In brief, 1 mL of internal standard (1 mg C13:0 TAG/mL acetone), 2 
mL of toluene, and 2 mL of 2% methanolic H2SO4 acid were added to 500 mg of ground feed 
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composites samples. The solution was heated at 50° C overnight. After cooling the samples to 
room temperature, 5 mL of 6% KHCO3 solution and 1 mL of hexane were added. The samples 
were mixed and centrifuged at 500 x g for 5 min. The resulting hexane layer was dried and 
cleaned over a mixture of sodium sulfate and charcoal. An aliquot of the solution, containing the 
fatty acid methyl esters (FAME), was taken for gas chromatograph (GC) analysis. The fatty acid 
composition of the differing treatment groups is shown in Table 2.   
Fatty acid analysis of adipose tissue.  3.75 mL of a chloroform/ methanol (1:2) mix was added to 
pre-weighed homogenized adipose tissue, sonicated and vortexed thoroughly to fully break down 
the tissue. 2.5 mL of chloroform and 1.25 mL of a 2% sodium chloride solution were added.  
After vortexing, and centrifuging to separate the layers, the lower chloroform layer containing 
the lipids was dried over anhydrous sodium sulfate. The chloroform phase was then dried under a 
stream of N2 and the resulting lipid extract was transesterified using 0.5 M sodium methoxide. 
The resulting fatty acid methyl esters (FAME) were subjected to the GC.   
Fatty acid analysis of muscle. Muscle tissue was homogenized in 5 mL methanol using an Ultra-
Turrax. 5 mL of chloroform was added and the mixture was vortexed then sonicated in a water 
bath for 15 min before being shaken over night to obtain full denaturation of the cell membranes. 
After 12 hours, 5 mL of 2% sodium chloride solution and 5 mL chloroform were added. The 
sample was then centrifuged for 15 minutes at 8°C at 4000 rpm.  The chloroform layer was dried 
over anhydrous sodium sulfate and evaporated under a stream of N2 to obtain the lipid extract. 
Lipids were transesterified using a two-step transesterification process using 0.5 M sodium 
methoxide and 10% boron trifluoride in methanol.  The resulting FAME solution was analyzed 
on a GC-2010 gas chromatograph (Shimadzu, Kyoto, Japan) equipped with a split injector, a 
flame ionization detector, an autosampler (model AOC-20s; Shimadzu), and a 100 m CP-Sil 88 
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fused-silica capillary column (100 m × 0.25 mm i.d. × 0.2 µm film thickness; Varian Inc., Palo 
Alto, CA) The injector and detector were both maintained at 250°C. Hydrogen was used as 
carrier gas at a linear velocity of 30 cm/sec. The sample injection volume was 1 µL at a split 
ratio between 1:100 and 1:5.  The oven program used was: initial temperature of 45°C held for 4 
min, programmed at 13°C/min to 175°C held for 27 min, then programmed at 4°C/min to 215°C 
held for 35 min. Integration and quantification was based on the FID response and achieved with 
GCsolution software (version 2.30.00, Shimadzu, Kyoto, Japan). Identification of FAME was 
accomplished by comparison of relative retention times with commercial FAME standards (37-
Component FAME mix, cis/trans FAME mix, and PUFA No. 3 mix from Supelco Inc., 
Bellefonte, PA, USA; CLA mixture #UC-59 M from Nu-Chek Prep. Elysian, MN USA). The 
fatty acid results were expressed as percentages (weight/weight) of fatty acids detected with a 
chain length between 10 and 24 carbon atoms. The lowest level of detection was <0.001g/100g 
fatty acids. 
Statistical analysis. Statistical analyses were performed with JMP Pro 11.0 software (SAS 
Institute Inc., Cary, NC). The results are expressed as mean ± SEM. A two-way ANOVA (with 
Tukey’s post hoc test) was used to compare fat level and treatment groups for all basal and 
endpoint data, as well as muscle and adipose tissue fatty acid composition.  Glucose homeostasis 
data were analyzed and displayed using GraphPad Prism. Significance was determined at p < 
0.05 and a trend was considered at p < 0.1.   
RESULTS 
Body weights and feed intake.  The average feed efficiency was significantly different between 
the HF and LF diets but not within the EO and FO groups (Table 3).  While total weight gain and 
8	  
	  
`	  
the feed efficiency ratio between the n-3 supplemented groups did not differ significantly within 
the HF and LF groups, there was a significant difference in energy intake (p < 0.001) in the HF-
EO group. This group displayed an increased energy intake that was not reflected in net weight 
gain, whereas the LF-FO group had a large energy intake that resulted in a trend towards heavier 
mice by the end of the study.  The ratios of the liver to body weight were significantly different 
between the HF CON and HF EO groups, with EO having a larger ratio when compared to the 
CON and FO groups (Table 3).  
Fed  plasma glucose and insulin measurements.  Plasma glucose and insulin concentrations were 
significantly different between the HF and LF groups but not within the EO and FO treatment 
groups (Table 3).   
IPGTT and IPITTs.   Figure 1 shows the IPGTT’s performed on the mice at three different time 
points and their corresponding area under the curve (AUC) calculations. There was significant 
difference (p < 0.01) between the HF and their respective LF counterparts but not within the EO 
and FO treatment groups (Figure 1, panel A and B). By week 12, the endpoint of the study, there 
were significant differences between the HF and their respective LF counterparts as well as 
between the EO group and the CON group for both the LF and HF groups.  For the IPITTs 
(Figure 2), there were no differences within the HF or LF groups at week 8, but all HF groups 
exhibited reduced insulin tolerance by 12 weeks. Therefore, EO supplementation improved 
glucose tolerance without affecting insulin tolerance by 12 weeks (Figure 1 and 2).   
Tissue fatty acid composition.  Despite the focus on the concentrations of SDA found in both the 
EO and FO diets (Table 1), there was no detectable presence of SDA within the fatty acid 
compositions of either adipose or muscle tissue in any of the EO or FO diets regardless of fat 
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level (Table 4 and 5 respectively).  For adipose tissue, the HF-EO group showed a significantly 
lower value for palmitic acid (16:0), stearic acid (18:0), oleic acid (18:1 n-9), vaccenic acid (18:1 
n-7), and linoleic acid (18:2 n-6) compared to the other diets. Compared to FO within both fat 
groups, the EO group also had significantly lower concentrations of total saturated fatty acids 
(SFAs) in the adipose and muscle tissue. Moreover, within the HF group, EO had higher 
concentrations of total PUFAs than FO and CON.  For EPA (20:5 n-3) and DHA (22:6 n-3), two 
important biomarkers of improved glucose homeostasis, in both the adipose and muscle tissues, 
the FO group demonstrated a significantly larger amount compared to both CON and EO in the 
LF and HF diets, and EO showed no significant difference when compared to CON but there was 
a strong trend (p < 0.1) illustrating an increased percentage of EPA and DHA. The EO group 
also displayed a significantly higher percentage of n-3 PUFAs than FO and CON in HF, and 
CON in LF with a strong trend (p < 0.1) towards a higher percentage than FO in the LF diet.  
The muscle tissue demonstrated no difference of n-3 fatty acids between EO and FO, but EO was 
significantly higher than the CON in the LF treatment. Therefore, EO group’s tissues contained 
higher amounts of EPA and DHA compared to the CON, had a greater amount of n-3 fatty acids, 
and contained higher PUFAs and lower SFAs.   
DISCUSSION: 
The goal of this study was to determine if a SDA-rich plant source such as Echium oil could 
provide similar positive effects as fish oil on the prevention of pre-diabetes by improving glucose 
homeostasis through the metabolism (elongation and desaturation) of SDA to its bioactive 
conversion products EPA and DHA. A HF diet-induced obesity model was used as a result of 
their expression of traits that are similar to humans, “pre-T2D” such as reduced glucose 
tolerance, hyperinsulinemia, and insulin resistance [4].       
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The increased energy intake in the HF-EO group that is not reflected in net weight gain may be 
explained by a higher energy metabolism in the EO mice than in the FO mice. The HF-EO mice 
also exhibited a lower epididymal fat weight/ body weight ratio, suggesting that although they 
were eating more, extra energy was either deposited into subcutaneous fat depots, which 
contribute little to systemic insulin resistance [3], or perhaps contributed to muscle mass.  
Mild hyperglycemia was observed in the HF diet groups with no differences among the n-3 
supplemented groups compared to the HF CON group. Hyperinsulinemia, the hallmark of pre-
diabetes and insulin resistance [6] was on the average 2-fold increased over the 12 week study in 
all HF groups compared to their respective LF groups. Whereas IPITT to measure insulin 
resistance demonstrated no improvements in insulin tolerance in the n-3 supplemented HF 
groups compared to their respective controls, the 12 week IPGTT revealed a significantly  
improved glucose tolerance in the EO-supplemented LF and HF groups compared to their 
control groups (p < 0.05). Hence, it appears that under these dietary conditions, EO is superior to 
FO at maintaining normal glucose tolerance, a function of both prevailing tissue glucose uptake 
activity and the ß-cell’s secretion of insulin [12].  This finding is consistent with previous data on 
EO’s effect on glucose disposal by Kavanagh [10] where they established that glucose disposal 
improved in insulin resistant monkeys on an EO diet. This improvement was not seen at the 
earlier time-points suggesting that it may take a few weeks for dietary supplements to affect 
glucose disposal, although this delay was not seen in the study of Kavanagh’s et al., where the 
glucose tolerance was noticed by the six-week mark [10].  This disparity may reflect the 
difference in species, and the slightly higher percentage of GLA found in the EO diet.  The 8-
week IPITT revealed that the HF-FO group transiently improved their insulin sensitivity, as by 
12 weeks, their values were no different from the HF-CON group.   
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Both the adipose and muscle tissue fatty acid analyses displayed distinct and intriguing fatty acid 
deposition patterns. There was no SDA detected in either of the tissues, which is at odds with 
some reports [2], but similar to others [10] which also was unable to detect SDA in muscle 
tissue. The lack of this fatty acid within the tissues may be due to the small percentage it 
contributed to the fat in the diets (LF-EO: 1.00% and HF-EO: 2.22% of total fatty acids), and the 
possibility that it was potentially converted efficiently into EPA and DHA, as seen in the 
increased amount found in EO compared to CON (p < 0.1).   While the amount of DHA and 
EPA found in the EO diet was not as high as that found in the FO diets, this is to be expected as 
the FO diets contained a large amount of EPA and DHA.  The EO diets, containing significantly 
smaller levels of EPA and DHA (not detected in LF-EO and only 0.05 g EPA/100 g of fatty 
acids of total fatty acids in HF-EO), depended on the metabolism of SDA to derive EPA and 
DHA in the tissues. These results are again similar to those found in Kavanagh’s study, where an 
increase in n-3 PUFAs, DHA and EPA, was detected upon EO supplementation, particularly in 
muscle tissue [10]. This, in turn, suggests that SDA in the EO diet was likely not responsible for 
the improved glucose tolerance. As there was no SDA found in the adipose or muscle tissue, it is 
unlikely to have contributed to the enhanced glucose tolerance. However, a potential source for 
the enhanced glucose tolerance may be attributed to gamma-linolenic acid (GLA; 18:3 n-6). This 
fatty acid was in the EO diet almost to the same extent as SDA (LF-EO had 0.76 g/100 g of fatty 
acids and HF-EO had 1.68 g/100 g of fatty acids), but was incorporated into both adipose and 
muscle tissue to detectable levels that were significantly higher (p < 0 .01 in muscle; p < 0.001 in 
adipose tissue) than the FO and CON groups. Kavanagh et al. [10] also attributed the increase in 
glucose tolerance found in the EO-fed group to GLA found in the tissues. 
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Another important difference to note was that of the percentage of SFA and PUFAs between 
treatment groups in the LF and HF diets in muscle tissue. According to the analysis of previous 
studies done by Micha and Mozaffarian [11], it has been shown that replacing SFAs with PUFAs 
aids in cardiovascular and diabetes prevention .The EO group demonstrated a significantly lower 
SFA and a higher PUFA incorporation in both muscle and adipose tissue than the CON and even 
the FO groups. This may be an indication of EO’s potential benefits in the improvement of 
glucose homeostasis under conditions of a diabetogenic diet.     
In summary, dietary Echium oil exhibits some distinct physiological effects compared to fish oil 
through the tissue specific incorporation of bioactive lipids and its capacity to maintain glucose 
homeostasis when superimposed with a diet rich in saturated fat. We have shown that dietary 
Echium oil improves glucose homeostasis, suggesting that it may (1) enhance systemic glucose 
uptake and possibly ß-cell function, (2) leads to reduced visceral adipose accumulation, and (3) 
increases tissue PUFA accumulation while reducing tissue SFA accumulation. Therefore, our 
study indicates that Echium oil can improve energy metabolism at multiple levels and is a 
promising sustainable n-3 source with several favorable physiological attributes. However, 
further work is required to more fully examine its efficacy over fish oil and the underlying 
mechanisms.   
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TABLES/ FIGURES 
 
Table 1: Composition of experimental diets fed to mice for 12 weeks. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Table 2: Fatty acid composition of the experimental diets fed to mice for 12 weeks (g/100 g total 
fatty acids, ND = not detected). 
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Table 3: Basal and endpoint measurements in LF or HF diet-fed mice (control, CON; fish oil, FO; echium oil, EO). 
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Table 4: Fatty acid composition of adipose tissue (g/100g total fatty acids)	  in LF or HF diet-fed mice (control, 
CON; fish oil, FO; echium oil, EO).  
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Table 5: Fatty acid composition of muscle tissue (g/100g total fatty acids) in LF or HF diet-fed mice (control, CON; fish 
oil, FO; echium oil, EO). 
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FIGURE LEGEND: 
Figure 1: Glucose tolerance tests (IPGTT) and their corresponding area under the curve (AUC).  
Values represent means ± SEM.  Panel A) IPGTT at 4 weeks (n=60), panel B) IPGTT at 8 weeks 
(n=30), and panel C) IPGTT at 12 weeks (n=30).	  Values represent means ± SEM. * p<0.05. 
Figure 2: Insulin tolerance tests (IPITT) and the corresponding area under the curve (AUC).  
Values represent means ±SEM.  Panel A) IPITT at 8 weeks (n=30) and panel B) IPITT at 12 
weeks (n=30). Values represent means ± SEM. * p<0.05.	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